These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 20841516

  • 1. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN, Shanholtz CB, Thompson JL.
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M, Redd R, Ni J, Stone RM, DeAngelo DJ, McDonnell AM.
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
    Campara M, Shord SS, Haaf CM.
    J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
    [Abstract] [Full Text] [Related]

  • 10. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA, Herrera N, Rohatgi R.
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R, Sinha S, Nirni SS, Patil SG, Pedapenki RM.
    Indian J Cancer; 2014 Oct; 51(2):180-3. PubMed ID: 25104205
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD, Ajiboye VO.
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
    Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE.
    Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
    [Abstract] [Full Text] [Related]

  • 20. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
    Khalighi PR, Martens KL, White AA, Li S, Silgard E, Frieze D, Garcia DA, Li A.
    J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.